AUTHOR
Mick Weinstein
380 postsYou may also like
Patrick O’Hare, chief market analyst at Briefing.com, makes the case for financials as an investment.
In June, the American Society of Clinical Oncology (ASCO) hosted its 60th Annual Meeting, drawing over 40,000 attendees from around the globe. This year’s event largely focused on validating revolutionary treatment categories like Chimeric antigen receptor (CAR) T-cell therapies and antibody drug conjugates (ADCs). Given proven clinical benefits across a wider array of cancer types, we expect these novel treatment categories to become increasingly important in the fight against cancer and the growth profiles of select companies in the healthcare space.
August marked the fourth consecutive month without an increase in margin levels. But can that explain why the stock market has been stuck?
The odds of a rate hike later this month are low